+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Fibroblast Growth Factor 2 (FGFR2) - Pipeline Insight, 2024 - Product Thumbnail Image

Fibroblast Growth Factor 2 (FGFR2) - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 100 Pages
  • Global
From
Enhancer of zeste homolog 2 protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Enhancer of zeste homolog 2 protein inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
Venglustat, Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Venglustat, Emerging Drug Insight and Market Forecast - 2032

  • Report
  • August 2022
  • 30 Pages
  • Global
From
GALAFOLD, Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

GALAFOLD, Drug Insight and Market Forecast - 2032

  • Report
  • August 2022
  • 30 Pages
  • Global
From
FABRAZYME, Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

FABRAZYME, Drug Insight and Market Forecast - 2032

  • Report
  • August 2022
  • 30 Pages
  • Global
From
From
Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Product Thumbnail Image

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist

  • Clinical Trials
  • June 2022
  • 65 Pages
  • Global
From
AL Amyloidosis - Epidemiology Forecast - 2032 - Product Thumbnail Image

AL Amyloidosis - Epidemiology Forecast - 2032

  • Drug Pipelines
  • March 2022
  • 83 Pages
  • Global
From
From
Fabry Disease - Epidemiology Forecast to 2032 - Product Thumbnail Image

Fabry Disease - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Gaucher's disease - Epidemiology Forecast to 2032 - Product Thumbnail Image

Gaucher's disease - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Palmar Hyperhidrosis - Epidemiology Forecast to 2032 (US) - Product Thumbnail Image

Palmar Hyperhidrosis - Epidemiology Forecast to 2032 (US)

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
Hunter Syndrome - Epidemiology Forecast to 2032 - Product Thumbnail Image

Hunter Syndrome - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more